These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 34289449)
1. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer. Wu J; Xu W; Ma L; Sheng J; Ye M; Chen H; Zhang Y; Wang B; Liao M; Meng T; Zhou Y; Chen H Aging (Albany NY); 2021 Jul; 13(14):18191-18222. PubMed ID: 34289449 [TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer. Zhang X; Li F; Zhou Y; Mao F; Lin Y; Shen S; Li Y; Zhang S; Sun Q Cell Death Dis; 2021 Jun; 12(7):627. PubMed ID: 34145213 [TBL] [Abstract][Full Text] [Related]
3. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression. Zhang X; Zhou Y; Mao F; Lin Y; Shen S; Sun Q Sci Rep; 2020 May; 10(1):7662. PubMed ID: 32376943 [TBL] [Abstract][Full Text] [Related]
4. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982 [TBL] [Abstract][Full Text] [Related]
5. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy. Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923 [TBL] [Abstract][Full Text] [Related]
6. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis. Han C; Fu Y; Zeng N; Yin J; Li Q Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085 [TBL] [Abstract][Full Text] [Related]
7. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis. Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083 [TBL] [Abstract][Full Text] [Related]
8. The knockdown of LncRNA AFAP1-AS1 suppressed cell proliferation, migration, and invasion, and promoted apoptosis by regulating miR-545-3p/hepatoma-derived growth factor axis in lung cancer. Sun J; Min H; Yu L; Yu G; Shi Y; Sun J Anticancer Drugs; 2021 Jan; 32(1):11-21. PubMed ID: 33290312 [TBL] [Abstract][Full Text] [Related]
9. Actin filament-associated protein 1-antisense RNA1 promotes the development and invasion of tongue squamous cell carcinoma via the AFAP1-AS1/miR-133a-5p/ZIC2 axis. Tang M; Wu H; Zhang H; Xu X; Jiang B; Chen Q; Wei Y; Qian H; Han L J Gene Med; 2024 Jan; 26(1):e3654. PubMed ID: 38282153 [TBL] [Abstract][Full Text] [Related]
10. Exploring the regulatory role of FBXL19-AS1 in triple-negative breast cancer through the miR-378a-3p/OTUB2 axis. Guo C; Zhang M; Jin X; Zhu C; Qian J; Tao M Cell Biochem Funct; 2024 Jun; 42(4):e4020. PubMed ID: 38702967 [TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA SOX21-AS1 regulates the progression of triple-negative breast cancer through regulation of miR-520a-5p/ORMDL3 axis. Liu X; Song J; Kang Y; Wang Y; Chen A J Cell Biochem; 2020 Nov; 121(11):4601-4611. PubMed ID: 32277517 [TBL] [Abstract][Full Text] [Related]
12. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway. Zhu S; Sun J; Liu X; Shao H; Feng C; Wang Z; Zheng X; Wei S Mol Cell Biol; 2022 Jun; 42(6):e0018821. PubMed ID: 35499320 [TBL] [Abstract][Full Text] [Related]
13. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. Zheng S; Li M; Miao K; Xu H J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053 [TBL] [Abstract][Full Text] [Related]
14. A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer. Sun J; Li X; Yu E; Liu J; Sun L; He Q; Lu Q Diagn Pathol; 2021 May; 16(1):45. PubMed ID: 34006305 [TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway. Qiao Y; Wang B; Yan Y; Niu L Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485 [TBL] [Abstract][Full Text] [Related]
16. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling. Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420 [TBL] [Abstract][Full Text] [Related]
17. LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis. Leng W; Liu Q; Zhang S; Sun D; Guo Y Cancer Biol Ther; 2020 Nov; 21(11):1072-1080. PubMed ID: 33138677 [TBL] [Abstract][Full Text] [Related]
18. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p. Xing L; Tang X; Wu K; Huang X; Yi Y; Huan J Aging (Albany NY); 2020 Dec; 13(1):424-436. PubMed ID: 33290256 [TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA AFAP1-AS1 facilitates ovarian cancer progression by regulating the miR-107/PDK4 axis. Liu B; Yan L; Chi Y; Sun Y; Yang X J Ovarian Res; 2021 Apr; 14(1):60. PubMed ID: 33926489 [TBL] [Abstract][Full Text] [Related]
20. LncRNA AFAP1-AS1 Knockdown Represses Cell Proliferation, Migration, and Induced Apoptosis in Breast Cancer by Downregulating Cai B; Wang X; Bu Q; Li P; Xue Q; Zhang J; Ding P; Sun D Cancer Biother Radiopharm; 2022 Oct; 37(8):662-672. PubMed ID: 32955920 [No Abstract] [Full Text] [Related] [Next] [New Search]